Algorithm for the treatment of acute psychotic episodes

Psychiatry and Clinical Neurosciences

Volumn 53, Issue SUPPL., 1999, Pages

  Hayashida, Masaki ^a   Nakane, Yoshibumi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Algorithm; Psychopharmacology; Schizophrenia; Treatment

Indexed keywords

NEUROLEPTIC AGENT;

ALGORITHM; CLINICAL PRACTICE; CONFERENCE PAPER; HUMAN; JAPAN; PRESCRIPTION; PSYCHIATRIC TREATMENT; PSYCHIATRIST; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT PLANNING;

ACUTE DISEASE; ALGORITHMS; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; JAPAN; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 0032746335     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Anzai N, Okazaki Y, Miyauchi M et al. Early neuroleptic medication within one year after onset can reduce risk of later relapses in schizophrenic patients? 5 year follow-up study testing T.J. Crow's hypothesis. Annual Report Pharmacopsychiatry Research Foundation 1988; 19:258-265 (in Japanese).
2. Okazaki Y, Shimogawa S. Pharmacotherapy in acute phase of schizophrenia, In: Yagi G (ed.) Pharmacotherapy in Psychiatry, Seishinka-MOOK extra 1. Kanehara & Co. Ltd, Tokyo, 1989; 228-242 (in Japanese).
3. Yagi G, Kanba S, Inada T. Pharmacotherapy and longterm prognosis of schizophrenia. Rinsho Seishin Igaku 1992; 21:1013-1021 (in Japanese).
4. Minami H, Nakahara T, Miyahara A, Nakane Y. Prediction of drug responses in schizophrenia: A method using a test dose of chlorpromazine. Psychiatry Clin. Neurosci. 1997; 51: 217-222.
5. Ogura C, Ota I. Response of antipsychotic drugs in schizophrenics. Shinkei Seishin Yakuri 1995; 17: 833-841 (in Japanese).
6. Yagi G, Kanba S, Inada T. Psychopharmacology of the positive and negative symptoms in schizophrenia: Pharmacotherapy. Rinsho Seishin Igaku 1994; 23: 1305-1310 (in Japanese).
7. Srivastava JS, Okazaki Y, Nakane Y. Responsivity of negative symptoms to typical neuroleptic drugs in schizophrenia. Acta Med. Nagasaki 1996; 41:8-14.
8. Bertolote JM, de Girolamo G (eds). Essential Drugs in Psychiatry. Division of Mental Health, World Health Organization, Geneva, 1993.
9. Zarate Jr CA, Daniel DG, Kinon BJ et al Algorithms for the treatment of schizophrenia. Psychopharmacol. Bull. 1995; 31:461-467.
10. Frances A, Docherty JP, Kahn DA. The expert consensus guideline series: Treatment of schizophrenia. J. Clin. Psychiatry 1996; 57 (Suppl. 12B): 1-59.
11. Frangou S, Murray RM. Schizophrenia. Martin Dunitz, London, 1996.
12. Itoh H. Pharmacotherapy of schizophrenia: Its present status and controversial points. Seishin Igaku 1985; 27: 521-530 (in Japanese).
13. Andreasen NC (translated by Okazaki Y, Anzai N, Ohta T et al.). The Scale for the Assessment of Negative Symptoms (SANS). Rinsho Seishin Igaku 1984; 13: 999-1010.
14. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Rating Manual (Jpn edn, translated by Yamada H, Masui K, Kikumoto K.). Seiwa Shoten Publishers, Tokyo, 1991 (in Japanese).
15. Someya T. Rating scales for positive and negative symptoms in schizophrenia. Rinsho Seishin Igaku 1994; 23: 1297-1304 (in Japanese).
16. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol. Rep. 1962; 10:799-812.
17. Yagi G. Pharinacotherapeutics of Schizophrenia on Neo-Hippocratic Viewpoint. Kanehara & Co. Ltd, Tokyo, 1993 (in Japanese).
18. Nakane Y. Childhood schizophrenia. In: Honjo H (ed.) Today's Treatments in Child Psychiatry. Kongo Shuppan, Tokyo, 1996; 202-214 (in Japanese).
19. Kan R, Watabe M, Kumashiro H. The rational use of psychotropic drugs in pregnant women. Rinsho Seishin Igaku 1991; 20:303-308 (in Japanese).
20. Kato T, Arai M. Maternal haloperidol effects on pregnancy and development of the children. Psychiatria Neurologia Japonica 1990; 92:277-293 (in Japanese).
21. Otsuki S. Rational selection of antipsychotics in the treatment of schizophrenia. Seishinka Chiryogaku 1993; 8:3-10 (in Japanese).
22. Murasaki M. Pre-clinical and clinical pharmacology of risperidone. Shinkei Seishin Yakuri 1995; 17: 599-620 (in Japanese).
23. Lieberman JA. Treatment effects on the course of schizophrenia: Potential benefits of atypical antipsychotics in first episode patients. In: Brunello N, Racagni G, Langer SZ et al. (eds) Critical Issues in the Treatment of Schizophrenia 10. International Academy of Biomedical Drug Research, Basel, 1995; 106-114.
24. Okazaki Y, Ota T, Nakayasu N. A critical review of treatment with high doses of neuroleptics in schizophrenia. Shinkei Seishin Yakuri 1983; 5:411-425.
25. Möller H-J, Kissling W, Lang C et al. Efficacy and side effects of haloperidol in psychotic patients: Oral versus intravenous administration. Am. J. Psychiatry 1982; 139: 1571-1575.
26. Obayashi S, Nakajima K, Matsushima E et al. Safety and effectiveness of modified electroconvulsive therapy. Seishinka Chitryogaku 1990; 5:203-211 (in Japanese).
27. Tsukishima T, Yasuda M. Utilization of a convulsive ECT on visit to patients with severe somatic complications in general hospital. Seishin Igaku 1996; 38: 423-425 (in Japanese).
28. Kumamoto S, Kunishige K. The present status of electroconvulsive therapy at department of neuropsychiatry in a public hospital. Rinsho Seishin Igaku 1997; 26: 611-621 (in Japanese).
29. Garza-Trevin̄o ES, Hollister LE, Overall JE. Efficacy of combination of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am. J. Psychiatry 1989; 146: 1598-1601.
30. Itoh H, Fujii Y. Psychotropic polypharmcy in Japan: Its present status and controversy on its merits and/or demerits. Shinkei Seishin Yakuri 1983; 5: 149-184 (in Japanese).
31. Kamijima K. Benzodiazepines antidepressants and lithium combinded with neuroleptics in schizophrenic patients. Seishinka Chiryogaku 1986; 1: 23-32 (in Japanese).
32. Little JD, Taghavi EH. Disinhibition after lorazepam augmentation of antipsychotic medication. Am. J. Psychiatry 1991; 148: 1099.
33. Shibasaki M, Someya T, Takahashi S. Pharmacokinetics of neuroleptic drugs: Drug metabolism and the utility of plasma level monitoring. Rinsho Seishin Igaku 1993; 22: 1101-1108 (in Japanese).
34. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch. Gen. Psychiatry 1991; 48: 739-745.
35. Hirokane G, Someya T, Shibasaki M et al. The interindividual difference of bromperidol. metabolism and its relationship to clinical effects. Rinsho Seishin Igaku 1996; 25: 1227-1237 (in Japanese).
36. Van Putten T, Marder SR, Mintz J et al. Haloperidol plasma levels and clinical response: A therapeutic window relationship. Am. J. Psychiatry 1992; 149: 500-505.
37. Volavka J, Cooper TB, Czobor P et al. Plasma haloperdol levels and clinical effects in schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 1995; 52: 837-845.
38. Someya T, Hirokane G, Ozeki Y et al. The present circumstances and the critical issues of therapeutic drug monitoring of haloperidol. Seishin Igaku 1996; 38: 835-842 (in Japanese).
39. Hirokane G, Someya T, Morita S et al. Some crucial aspects of therapeutic drug monitoring and therapeutic range of bromperidol. Shinkei Seishin Yakuri 1997; 19: 39-49 (in Japanese).
40. Wakamatsu N. Mechanism of action and clinical efficacy of substituted benzamides. Seishinka Chiryogaku 1993; 8: 27-38 (in Japanese).